Efficacy and Safety of Venus P-valve to Treat RVOT Stenosis With Pulmonary Regurgitation

Inclusion Criteria: * RVOT stenosis who have undergone transannular patch repair with moderate to severe pulmonary regurgitation * Isotopic or CMR criteria of RVEDVI≥130mL/m2 and ≤160mL/m2 * Age≥18 years and ≤60 years (Zhongshan Hospital age≥18 years and ≤60 years * Body weight≥18 kg * Pulmonary annular diameter between 14mm to 31mm * RVOT length≥20mm * The subject or his/her legal representative has provided written informed consent * Subject will comply with protocol required follow-ups Add any of the following conditions: * Subject is symptomatic * Subject presents with \>30% pulmonary regurgitation fraction as defined by cardiac MRI * ≥3+ pulmonary regurgitation by echocardiograms * Deteriorating RVEF% * Progressive tricuspid valve regurgitation (at least moderate degree) * Complicated with RVOT obstruction (RV systolic pressure\>80mmHg) * Persistent arrhythmias Exclusion Criteria: Candidates will be excluded from the study if any of the following conditions are present: * Existing pulmonary artery branch stenosis or artificial pulmonary valve * Severe chest wall deformity * ADHF * Active infection or endocarditis requiring antibiotic therapy * Leukopenia (WBC\<3000mm3) * Acute or chronic anemia (Hb\<9g/L) * Platelet account \<100,000 cells/mm3 * In the judgment of the investigator, percutaneous introduction and delivery of the valve is not feasible * A known hypersensitivity to aspirin or heparin * Positive urine or serum pregnancy test in female subjects * Ileofemoral vessel characteristics that would preclude safe placement of introducer sheath